ovarian-cancer

Documents about ovarian-cancer

• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors#18576ClinicalTrials.gov
• Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer#18621ClinicalTrials.gov
• A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer#67877ClinicalTrials.gov
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA#67893ClinicalTrials.gov
• Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer#67897ClinicalTrials.gov
• Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer#121452ClinicalTrials.gov
• HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer#346976ClinicalTrials.gov
• Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer#356469ClinicalTrials.gov
• Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer#356484ClinicalTrials.gov
• PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade#14277HAL (France)
• ID Card of Mcl-1 PROTAC degrader: From in silico design to biological validation in chemoresistant ovarian cancer#280401HAL (France)
• Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study#291637HAL (France)

Related topics